MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) INVESTOR ALERT Investors With Large Losses in MoonLake Immunotherapeutics Should Contact Bernstein Liebhard LLP To Discuss Their RightsNEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, inclusive.
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Rosen Law Firm Urges MoonLake Immunotherapeutics (NASDAQ: MLTX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of MoonLake Immunotherapeutics (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”). MoonLake is a clinical-stage biotechnology company.
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of the securities laws.
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (
NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public.
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of the securities laws.
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX).
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases that have significant unmet patient needs.
